LY354740, an agonist of glutamatergic metabotropic receptor mGlu2/3 increases the cytochrome P450 2D (CYP2D) activity in the frontal cortical area of rat brain
Repeated administration of the mGlu<sub>2/3</sub> receptor agonist, the compound LY354740 specifically increases the protein level and activity of CYP2D in the frontal cortex, which may accelerate dopamine synthesis via an alternative CYP2D-mediated route in the mesocortical dopaminergic pathway, and thus may contribute to the beneficial pharmacological effect on negative symptoms of schizophrenia.
Authors
- Ewa Bromek (ORCID: https://orcid.org/0000-0003-2440-0482)
- Renata Pukło (ORCID: https://orcid.org/0000-0003-4820-9084)
- Anna Haduch (ORCID: https://orcid.org/0000-0002-3925-3828)
- Władysława A. Daniel (ORCID: https://orcid.org/0000-0002-1226-1721)
Institutions
- Maj Institute of Pharmacology (PL)
- Polish Academy of Sciences (PL)
Publication Details
- Journal
- Pharmacological Reports
- Published
- 2024-11-04
- DOI
- https://doi.org/10.1007/s43440-024-00675-5
- Citations
- 2
- Primary Topic
- Neuroscience and Neuropharmacology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.54